• The Christie NHS Foundation Trust
• Oglesby Cancer Research Building
• The University of Manchester

Our interests span various aspects of the tumour microenvironment, including stroma and the extracellular matrix, inflammation, immunity, angiogenesis and hypoxia.

Much of the research into cell-matrix interaction takes place in the Wellcome Trust Centre for Cell Matrix Research at The University of Manchester.  This includes work focused on integrins and tissue stiffness in breast cancer, biological clocks and adhesion.

At the Cancer Research UK Manchester Institute, we are interested in how tumour cells exchange information with non-mutated host cells, such as immune cells, fibroblasts and endothelial cells, to support tumour growth and resistance to therapies. Others at the Institute are focusing on the mechanisms underlying natural and therapy-induced tumour immunity, with a particular emphasis on identifying the cellular and molecular mediators that regulate the balance between tumour-protective versus tumour-promoting inflammation. This research feeds into our wider Immuno-oncology theme.

Within the University, our researchers are exploring the role of hypoxia in tumour radiobiology, developing predictive biomarkers for clinical practice. We are also implementing novel MR-based imaging approaches to detecting and quantifying variations in tumour oxygenation in vivo. Our scientists are also looking to exploit tumour hypoxia and its associated transcription factors for therapeutic benefit.

Institute scientists, as well as groups in Pharmacy, are investigating MAP kinases and other intracellular signaling molecules and how they control and promote tumour growth, progression and spread.

Elsewhere, there are interests in clotting, growth factors and angiogenesis. Parallel research involving the synthesis of competitive inhibitors of heparan sulfate alongside clinical trials of existing and new anti-angiogenic agents aims halt cancer growth by blocking the growth of blood vessels. Separately, we are looking at coagulation and its relationship with prognosis.



Medical Oncology